Financials data is unavailable for this security.
View more
Year on year BB Biotech AG had revenues fall -57.97% from 1.26m to 530.00k, though the company grew net income from a loss of 357.81m to a smaller loss of 206.61m.
| Gross margin | 97.74% |
|---|---|
| Net profit margin | 113.67% |
| Operating margin | 113.76% |
| Return on assets | 11.35% |
|---|---|
| Return on equity | 12.96% |
| Return on investment | 12.96% |
More ▼
Cash flow in CHFView more
In 2023, cash reserves at BB Biotech AG fell by 1.45m. However, the company earned 218.28m from its operations for a Cash Flow Margin of 41,184.15%. In addition the company used on investing activities and also paid 220.21m in financing cash flows.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 45.11 |
|---|---|
| Tangible book value per share | 45.11 |
More ▼
Balance sheet in CHFView more
| Current ratio | 7.99 |
|---|---|
| Quick ratio | -- |
| Total debt/total equity | 0.1393 |
|---|---|
| Total debt/total capital | 0.1223 |
More ▼
Growth rates in CHF
Year on year, growth in dividends per share fell -29.82% while earnings per share excluding extraordinary items rose 42.08%. Additionally, five year annualized dividend per share growth ranks below the industry average relative to its peers.
| Div yield(5 year avg) | 4.96% |
|---|---|
| Div growth rate (5 year) | -8.09% |
| Payout ratio (TTM) | 36.00% |
| EPS growth(5 years) | -- |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 199.02 |
More ▼
